Boston, MA - Putting mice on a diet containing low amounts of the essential amino acid methionine triggered the formation of new blood vessels in skeletal muscle, according to a new study from Harvard T.H. Chan School of Public Health. The finding adds insight to previous research showing that a methionine-restricted diet extends lifespan and healthspan, suggesting that improved vascular function may contribute to these benefits.
"The benefits of methionine restriction in rodents are fascinating because they resemble those of calorie restriction, but without enforced restriction of food intake," said senior author James Mitchell, associate professor of genetics and complex diseases.
The study appears online March 22, 2018 in Cell.
Previous work by Mitchell and colleagues has shown that a methionine-restricted diet increases production of the gas, hydrogen sulfide. This smelly molecule gives rotten eggs their characteristic odor, but is also made in our cells where it functions in myriad beneficial ways. One of these is to promote the growth of new blood vessels from endothelial cells--a process known as angiogenesis. So the researchers decided to test whether there was a direct connection between a methionine-restricted diet and angiogenesis.
They fed mice a synthetic diet containing limited methionine and lacking the only other sulfur-containing amino acid, cysteine. These two amino acids are found in high amounts in protein-rich foods such as meats, dairy, nuts, and soy. After two months, the diet-restricted mice had increased the number of small blood vessels, or capillaries, in skeletal muscles compared to mice fed a control diet.
Lack of oxygen, or hypoxia, is the best-characterized trigger of angiogenesis. Hypoxia occurs in tissues when a vessel is blocked, or upon acute exercise when oxygen delivery is limited. However, methionine restriction triggered angiogenesis despite normal oxygen delivery, suggesting involvement of a pathway sensing amino acid deprivation rather than hypoxia. The authors identified a requirement for the amino acid-sensing kinase GCN2 and the transcription factor ATF4 in angiogenesis triggered by methionine restriction.
These findings may provide important new targets for modulating angiogenesis in the future. Depending on the clinical context, this could include promoting angiogenesis, for example in the context of aging or vascular disease in which improved blood flow to ischemic tissues is required, or inhibiting angiogenesis where blocking new blood vessel formation could prevent tumor growth.
In an accompanying paper from David Sinclair's group at Harvard Medical School published in the same issue of Cell, the authors found that treatment with NMN--a small molecule activator of the longevity-associated protein SIRT1--either alone or in combination with hydrogen sulfide (in the form of NaHS), increased vascular density in the skeletal muscle of elderly mice and boosted the aging animals' exercise capacity.
"We believe our findings help set the stage for therapies for a spectrum of diseases that arise from blood vessel demise," said Sinclair, professor of genetics at Harvard Medical School and co-director of the Paul F. Glenn Center for the Biology of Aging there.
Taken together, these studies point to new dietary and pharmacological approaches to improving vascular health in rodents by promoting blood vessel formation in skeletal muscle. Future studies will be required to test whether such approaches can be translated to humans.
Other Harvard Chan authors include Alban Longchamp, Alessandro Arduini, Michael MacArthur, J. Humberto Trevino-Villarreal, Christopher Hine, Issam Ben-Sahra, Nelson Knudsen, Lear Brace, Justin Reynolds, Pedro Mejia, Chih-Hao Lee, and Brendan Manning. Longchamp, Arduini, and Teodelinda Mirabella from Boston University shared co-first authorship.
This work was supported by grants from the Swiss National Science Foundation (P1LAP3_158895) to A.L.; the National Science Foundation (NSF-DGE1144152) to L.E.B.; the Canadian Institutes of Health Sciences to R.W.; the NIH (EB00262) to C.S.C.; the American Heart Association (12GRNT9510001 and 12GRNT1207025), the Lea Carpenter du Pont Vascular Q1 Surgery Fund, and the Carl and Ruth Shapiro Family Foundation to C.K.O.; and the NIH (AG036712 and DK090629) and the Charoen Pokphand Group to J.R.M.
"Amino Acid Restriction Triggers Angiogenesis via GCN2/ATF4 Regulation of VEGF and H2S Production," Alban Longchamp, Teodelinda Mirabella, Alessandro Arduini, Michael R. MacArthur, Abhirup Das, J. Humberto Trevino-Villarreal, Christopher Hine, Issam Ben-Sahra, Nelson H. Knudsen, Lear E. Brace, Justin Reynolds, Pedro Mejia, Ming Tao, Gaurav Sharma, Rui Wang, Jean-Marc Corpataux, Jacques-Antoine Haefliger, Kyo Han Ahn, Chih-Hao Lee, Brendan D. Manning, David A. Sinclair, Christopher S. Chen, C. Keith Ozaki, and James R. Mitchell, Cell, online March 22, 2018, doi: 10.1016/j.cell.2018.03.001
Visit the Harvard Chan School website for the latest news, press releases, and multimedia offerings.
Harvard T.H. Chan School of Public Health brings together dedicated experts from many disciplines to educate new generations of global health leaders and produce powerful ideas that improve the lives and health of people everywhere. As a community of leading scientists, educators, and students, we work together to take innovative ideas from the laboratory to people's lives--not only making scientific breakthroughs, but also working to change individual behaviors, public policies, and health care practices. Each year, more than 400 faculty members at Harvard Chan School teach 1,000-plus full-time students from around the world and train thousands more through online and executive education courses. Founded in 1913 as the Harvard-MIT School of Health Officers, the School is recognized as America's oldest professional training program in public health.